BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BCRX
  • CUSIP: 09058V10
  • Web:
  • Market Cap: $329.75 million
  • Outstanding Shares: 80,428,000
Average Prices:
  • 50 Day Moving Avg: $5.18
  • 200 Day Moving Avg: $6.22
  • 52 Week Range: $3.75 - $9.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.39
  • P/E Growth: -0.29
Sales & Book Value:
  • Annual Revenue: $29.28 million
  • Price / Sales: 11.26
  • Book Value: $0.30 per share
  • Price / Book: 13.67
  • EBIDTA: ($42,940,000.00)
  • Net Margins: -160.97%
  • Return on Equity: -276.62%
  • Return on Assets: -44.43%
  • Debt-to-Equity Ratio: 0.94%
  • Current Ratio: 1.57%
  • Quick Ratio: 1.54%
  • Average Volume: 1.56 million shs.
  • Beta: 3.31
  • Short Ratio: 9.62

Frequently Asked Questions for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02. The firm earned $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. BioCryst Pharmaceuticals's quarterly revenue was down 35.4% on a year-over-year basis. During the same period last year, the firm earned ($0.22) EPS. View BioCryst Pharmaceuticals' Earnings History.

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?

8 brokers have issued 1 year price objectives for BioCryst Pharmaceuticals' stock. Their forecasts range from $6.00 to $11.00. On average, they expect BioCryst Pharmaceuticals' share price to reach $8.50 in the next twelve months. View Analyst Ratings for BioCryst Pharmaceuticals.

What are analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
  • 2. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:

  • Robert A. Ingram, Chairman of the Board
  • Jon P. Stonehouse, President, Chief Executive Officer, Director
  • Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
  • Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery
  • Lynne M Powell, Senior Vice President, Chief Commercial Officer
  • William P. Sheridan, Senior Vice President, Chief Medical Officer
  • Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary
  • Fred E. Cohen Ph.D., M.D., Director
  • Sanj K. Patel, Director
  • George B. Abercrombie, Independent Director

Who owns BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.47%), RA Capital Management LLC (6.42%), State Street Corp (4.86%), FLYNN JAMES E (4.25%), FMR LLC (3.89%) and VHCP Management II LLC (3.08%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Thomas R Staab II and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Who sold BioCryst Pharmaceuticals stock? Who is selling BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Federated Investors Inc. PA, JPMorgan Chase & Co., Emory University, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, California State Teachers Retirement System and Dynamic Technology Lab Private Ltd. Company insiders that have sold BioCryst Pharmaceuticals stock in the last year include Alane P Barnes, Thomas R Staab II and Yarlagadda S Babu. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Who bought BioCryst Pharmaceuticals stock? Who is buying BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, FMR LLC, State Street Corp, Vanguard Group Inc., Artal Group S.A., Jennison Associates LLC, OxFORD Asset Management LLP and TIAA CREF Investment Management LLC. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $4.10.

MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $8.50 (107.32% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Noble FinancialReiterated RatingBuyLowView Rating Details
8/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/28/2017Jefferies Group LLCBoost Price TargetPositive$3.50 -> $6.00N/AView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00N/AView Rating Details
2/13/2017Piper Jaffray CompaniesReiterated RatingOverweight$8.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
8/5/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00N/AView Rating Details
11/11/2015Bank of America CorporationDowngradeNeutral -> Underperform$12.00 -> $10.00N/AView Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Earnings History by Quarter for BioCryst Pharmaceuticals (NASDAQ BCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.19)($0.21)$5.79 million$3.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 84.72%
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
DateHeadline logoBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Earnings of -$0.17 Per Share - August 13 at 12:06 AM logoZacks Investment Research Downgrades BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to Hold - August 10 at 4:32 PM logoJefferies Group Analysts Lower Earnings Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - August 10 at 12:10 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Upgraded to "Buy" at Zacks Investment Research - August 9 at 4:40 PM logoBioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 8 at 4:14 PM logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Buy" from Brokerages - August 8 at 2:44 PM logoEdited Transcript of BCRX earnings conference call or presentation 7-Aug-17 3:00pm GMT - August 8 at 1:58 AM logoBUZZ-US STOCKS ON THE MOVE-NxStage, Acorn, Armstrong, MyoKardia, On Deck - Nasdaq - August 7 at 3:54 PM logoBioCryst Reports Second Quarter 2017 Financial Results - August 7 at 3:54 PM logoBioCryst reports 2Q loss - August 7 at 3:54 PM logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Announces Earnings Results - August 7 at 8:50 AM logoBioCryst Pharmaceuticals misses by $0.02, misses on revenue - August 7 at 6:33 AM logoBioCryst Pharma (BCRX) Reports Initiation of ZENITH-1 - - August 3 at 10:52 PM logoBioCryst Pharma (BCRX) Reports Initiation of ZENITH-1 - August 2 at 5:11 PM logoBioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks - August 2 at 5:11 PM logoBioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : August 1, 2017 - August 1 at 11:07 PM logoTraders Buy Large Volume of Call Options on BioCryst Pharmaceuticals (BCRX) - July 31 at 8:48 AM logo$5.39 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter - July 27 at 10:58 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Scheduled to Post Earnings on Wednesday - July 26 at 7:32 AM logo-$0.19 EPS Expected for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Quarter - July 25 at 8:20 PM logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 24, 2017 - July 24 at 3:46 PM logoBioCryst to Announce Second Quarter 2017 Financial Results on August 7 - July 24 at 12:30 PM logoBioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : July 18, 2017 - July 18 at 5:57 PM logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of "Buy" from Analysts - July 14 at 3:19 PM logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 13, 2017 - July 13 at 5:23 PM logoToday's Research Reports on Stocks to Watch: BioCryst Pharmaceuticals and Exact Sciences - July 8 at 8:37 AM logoBioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : July 4, 2017 - July 4 at 8:11 PM logoBiotech Movers: BioCryst, Omeros, Radius Health - - July 3 at 3:16 PM logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : July 3, 2017 - July 3 at 3:16 PM logo Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $5.39 Million - July 1 at 8:53 AM logo Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Earnings of -$0.19 Per Share - June 29 at 4:34 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Update - June 29 at 7:24 AM logoZacks Investment Research Downgrades BioCryst Pharmaceuticals, Inc. (BCRX) to Sell - June 27 at 4:44 PM logoBioCryst Pharmaceuticals (BCRX) Presents At JMP Securities Life Sciences Conference - Slideshow - June 21 at 4:49 PM logoBioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : June 21, 2017 - June 21 at 4:49 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Buy" from Analysts - June 19 at 2:28 PM logoETFs with exposure to BioCryst Pharmaceuticals, Inc. : June 16, 2017 - June 16 at 4:34 PM logoBiotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics - June 15 at 5:37 PM logoBioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 10:37 AM logoShort Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Expands By 26.4% - June 11 at 7:14 AM logoBioCryst's Lead Candidate BCX7353 To Treat Hereditary Angioedema Inches Closer To The Market - Seeking Alpha - June 8 at 2:09 AM logoBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Quarterly Sales of $5.39 Million - June 7 at 10:40 AM logoBioCryst Pharmaceuticals (BCRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 6 at 4:00 PM logoFlu therapy from RTP's BioCryst could be available for kids next season - June 6 at 4:00 PM logoDown 24.6%, is BioCryst Pharmaceuticals Stock Now a Buy? - June 6 at 4:00 PM logoBioCryst Pharma (BCRX) Announces FDA Acceptance of RAPIVAB Pediatric sNDA; September 2017 PDUFA - - June 5 at 3:27 PM logo Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Earnings of -$0.19 Per Share - June 5 at 2:18 PM logoBioCryst Announces RAPIVAB® Pediatric sNDA Acceptance - June 5 at 12:51 PM logoBioCryst: Frustration Then Joy In Biotech Investing - Seeking Alpha - June 1 at 9:20 PM logoBioCryst Pharmaceuticals, Inc. (BCRX) Rating Reiterated by Noble Financial - May 30 at 12:46 AM



BioCryst Pharmaceuticals (BCRX) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff